

Archived Editions (COVID-19 Genomics and Precision Public Health Weekly Update)

Published on 06/10/2021

COVID-19 Genomics and Precision Public Health Weekly Update Content

- Pathogen and Human Genomics Studies
- Non-Genomics Precision Health Studies
- News, Reviews and Commentaries

Pathogen and Human Genomics Studies

- Vitamin D and COVID-19 susceptibility and severity in the COVID-19 Host Genetics Initiative: A Mendelian randomization study. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1283)
Butler-Laporte Guillaume et al. PLoS medicine 2021 6 (6) e1003605

In this 2-sample MR study, we did not observe evidence to support an association between 25OHD levels and COVID-19 susceptibility, severity, or hospitalization. Hence, vitamin D supplementation as a means of protecting against worsened COVID-19 outcomes is not supported by genetic evidence. Other therapeutic or preventative avenues should be given higher priority for COVID-19 randomized controlled trials.

- Pan-ancestry exome-wide association analyses of COVID-19 outcomes in 586,157 individuals (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1285)
JA Kosmicki et al, AJHG, June 2, 2021

We used exome-sequence data to investigate associations between rare genetic variants and seven COVID-19 outcomes in 586,157 individuals, including 20,952 with COVID-19. We did not identify any clear associations with rare variants either exome-wide or when specifically focusing on (i) 13 interferon pathway genes in which rare deleterious variants have been reported in individuals with severe COVID-19; (ii) 281 genes located in susceptibility loci identified by the COVID-19 Host Genetics Initiative; or (iii) 32 additional genes of immunologic relevance and/or therapeutic potential.

- A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T-cell responses (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1288)
A Tauzin et al, Cell Host and Microbe, June 4, 2021

To assess the mechanisms contributing to protection, we analyzed humoral and T cell responses three weeks after a single BNT162b2 dose. We observed weak neutralizing activity elicited in SARS-CoV-2 naïve individuals but strong anti-receptor binding domain and Spike antibodies with Fc-mediated effector functions and cellular CD4+ T cell responses. In previously-infected individuals, a single dose boosted all humoral and T-cell responses, with strong correlations between T helper and antibody immunity.

- Symptomatic Acute Myocarditis in Seven Adolescents Following Pfizer-BioNTech COVID-19 Vaccination (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1290)
M Marshall, Pediatrics, June 2021
- Spread of a SARS-CoV-2 variant through Europe in the summer of 2020 (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1296)
EB Hodcroft et al, Nature, June 7, 2021

We report on a novel SARS-CoV-2 variant, 20E (EU1), that emerged in Spain in early summer, and subsequently spread across Europe. We find no evidence of increased transmissibility, but instead demonstrate how rising incidence in Spain, resumption of travel, and lack of effective screening and containment may explain the variant's success. Despite travel restrictions, we estimate 20E (EU1) was introduced hundreds of times to European countries by summertime travelers, likely undermining local efforts to keep SARS-CoV-2 cases low.

- Would you have your DNA tested to predict how hard COVID-19 would strike? Should you? (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1297)
J Kaiser, Science, June 7, 2021

Several genetics experts tell Science that how a person's genes influence the course of COVID-19 remains too murky to deploy such risk assessments. "I think it's premature to use a genetic test to predict a person's likely COVID-19 severity. We don't understand exactly what these genetic variants mean or how they affect disease."

- SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1304)
S Gutmann et al, Nature Comms, June 7, 2021

We obtained blood samples (n=?2474) from hospitalized COVID-19 patients (n=?123), non-COVID-19 ICU sepsis patients (n=?25) and healthy controls (n=?30). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA was detected in plasma or serum (RNAemia) of COVID-19 ICU patients when neutralizing antibody response was low. RNAemia is associated with higher 28-day ICU mortality (hazard ratio [HR], 1.84 RNAemia is comparable in performance to the best protein predictors.

- Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1305)
O'Toole Áine et al. Wellcome open research 2021 6 121

Using a combination of data from routine surveillance, genomic sequencing and international travel we track the international dispersal of lineages B.1.1.7 and B.1.351 (variant 501Y-V2). We account for potential biases in genomic surveillance efforts by including passenger volumes from

location of where the lineage was first reported, London and South Africa respectively. Using the software tool grinch (global report investigating novel coronavirus haplotypes), we track the international spread of lineages of concern with automated daily reports.

- SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD and S2 (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1308)

F Amanat et al, Cell, June 7, 2021

We profiled vaccine-induced polyclonal antibodies as well as plasmablast derived mAbs from individuals who received SARS-CoV-2 spike mRNA vaccine. Polyclonal antibody responses in vaccinees were robust and comparable to or exceeded those seen after natural infection. However, the ratio of binding to neutralizing antibodies after vaccination was greater than that after natural infection and, at the monoclonal level, we found that the majority of vaccine-induced antibodies did not have neutralizing activity.

- Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1309)

G Alter et al, Nature, June 9, 2021

We report humoral and cellular immune responses from 20 Ad26.COV2.S vaccinated individuals from the COV1001 phase 1/2 clinical trial² against the original SARS-CoV-2 strain WA1/2020 as well as against the B.1.1.7, CAL.20C, P.1., and B.1.351 variants of concern. We show that neutralizing antibody responses induced by Ad26.COV2.S were reduced against the B.1.351 and P.1 variants, but functional non-neutralizing antibody responses and T cell responses were largely preserved against SARS-CoV-2 variants.

- Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1310)

E Pritchard et al, Nature Medicine, June 9, 2021

Using 1,945,071 real-time PCR results from nose and throat swabs taken from 383,812 participants between 1 December 2020 and 8 May 2021, we found that vaccination with the ChAdOx1 or BNT162b2 vaccines already reduced SARS-CoV-2 infections =21?d after the first dose (61% (95% confidence interval (CI))=?54–68%) versus 66% (95% CI=?60–71%), respectively), with greater reductions observed after a second dose (79% (95% CI=?65–88%) versus 80% (95% CI=?73–85%), respectively). The largest reductions were observed for symptomatic infections and/or infections with a higher viral burden.

- Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February?March 2021 (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1311)
Tober-Lau P, et al. Emerg Infect Dis, Jun 8, 2021.

One week after second vaccinations were administered, an outbreak of B.1.1.7 lineage severe acute respiratory syndrome coronavirus 2 infections occurred in a long-term care facility in Berlin, Germany, affecting 16/20 vaccinated and 4/4 unvaccinated residents. Despite considerable viral loads, vaccinated residents experienced mild symptoms and faster time to negative test results.

- Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1312)

Schwarz T, et al. Emerg Infect Dis, Jun 8, 2021.

We detected delayed and reduced antibody and T-cell responses after BNT162b2 vaccination in 71 elderly persons (median age 81 years) compared with 123 healthcare workers (median age 34 years) in Germany. These data emphasize that nonpharmaceutical interventions for coronavirus disease remain crucial and that additional immunizations for the elderly might become necessary.

- Vaccine Breakthrough Infections with SARS-CoV-2 Variants. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1314)
Hacisuleyman Ezgi et al. The New England journal of medicine 2021 4 (23) 2212-2218

We describe two fully vaccinated persons in whom subsequent breakthrough infections with SARS-CoV-2 variants harboring a number of substitutions of interest developed. Our observations provide support for current strategies to monitor multiple variables proactively. These strategies include viral testing of symptomatic and asymptomatic persons, sequencing of viral RNA, and monitoring of neutralizing antibody titers, particularly in vaccinated persons who subsequently become infected.

Non-Genomics Precision Health Studies

- Vitamin D and COVID-19 susceptibility and severity in the COVID-19 Host Genetics Initiative: A Mendelian randomization study. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1283)
Butler-Laporte Guillaume et al. PLoS medicine 2021 6 (6) e1003605

In this 2-sample MR study, we did not observe evidence to support an association between 25OHD levels and COVID-19 susceptibility, severity, or hospitalization. Hence, vitamin D supplementation as a means of protecting against worsened COVID-19 outcomes is not supported by genetic evidence. Other therapeutic or preventative avenues should be given higher priority for COVID-19 randomized controlled trials.

- Pan-ancestry exome-wide association analyses of COVID-19 outcomes in 586,157 individuals (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1285)
JA Kosmicki et al, AJHG, June 2, 2021

We used exome-sequence data to investigate associations between rare genetic variants and seven COVID-19 outcomes in 586,157 individuals, including 20,952 with COVID-19. We did not identify any clear associations with rare variants either exome-wide or when specifically focusing on (i) 13 interferon pathway genes in which rare deleterious variants have been reported in individuals with severe COVID-19; (ii) 281 genes located in susceptibility loci identified by the COVID-19 Host Genetics Initiative; or (iii) 32 additional genes of immunologic relevance and/or therapeutic potential.

- A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T-cell responses (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1288)
A Tauzin et al, Cell Host and Microbe, June 4, 2021

To assess the mechanisms contributing to protection, we analyzed humoral and T cell responses three weeks after a single BNT162b2 dose. We observed weak neutralizing activity elicited in

SARS-CoV-2 naïve individuals but strong anti-receptor binding domain and Spike antibodies with Fc-mediated effector functions and cellular CD4+ T cell responses. In previously-infected individuals, a single dose boosted all humoral and T-cell responses, with strong correlations between T helper and antibody immunity.

- Symptomatic Acute Myocarditis in Seven Adolescents Following Pfizer-BioNTech COVID-19 Vaccination (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1290)
M Marshall, Pediatrics, June 2021

- Spread of a SARS-CoV-2 variant through Europe in the summer of 2020 (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1296)
EB Hodcroft et al, Nature, June 7, 2021

We report on a novel SARS-CoV-2 variant, 20E (EU1), that emerged in Spain in early summer, and subsequently spread across Europe. We find no evidence of increased transmissibility, but instead demonstrate how rising incidence in Spain, resumption of travel, and lack of effective screening and containment may explain the variant's success. Despite travel restrictions, we estimate 20E (EU1) was introduced hundreds of times to European countries by summertime travelers, likely undermining local efforts to keep SARS-CoV-2 cases low.

- Would you have your DNA tested to predict how hard COVID-19 would strike? Should you? (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1297)
J Kaiser, Science, June 7, 2021

Several genetics experts tell Science that how a person's genes influence the course of COVID-19 remains too murky to deploy such risk assessments. "I think it's premature to use a genetic test to predict a person's likely COVID-19 severity. We don't understand exactly what these genetic variants mean or how they affect disease."

- SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1304)
S Gutmann et al, Nature Comms, June 7, 2021

We obtained blood samples (n=?2474) from hospitalized COVID-19 patients (n=?123), non-COVID-19 ICU sepsis patients (n=?25) and healthy controls (n=?30). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA was detected in plasma or serum (RNAemia) of COVID-19 ICU patients when neutralizing antibody response was low. RNAemia is associated with higher 28-day ICU mortality (hazard ratio [HR], 1.84 RNAemia is comparable in performance to the best protein predictors.

- Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1305)
O'Toole Áine et al. Wellcome open research 2021 6 121

Using a combination of data from routine surveillance, genomic sequencing and international travel we track the international dispersal of lineages B.1.1.7 and B.1.351 (variant 501Y-V2). We account for potential biases in genomic surveillance efforts by including passenger volumes from location of where the lineage was first reported, London and South Africa respectively. Using the

software tool grinch (global report investigating novel coronavirus haplotypes), we track the international spread of lineages of concern with automated daily reports.

- SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD and S2 (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1308)
F Amanat et al, Cell, June 7, 2021

We profiled vaccine-induced polyclonal antibodies as well as plasmablast derived mAbs from individuals who received SARS-CoV-2 spike mRNA vaccine. Polyclonal antibody responses in vaccinees were robust and comparable to or exceeded those seen after natural infection. However, the ratio of binding to neutralizing antibodies after vaccination was greater than that after natural infection and, at the monoclonal level, we found that the majority of vaccine-induced antibodies did not have neutralizing activity.

- Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1309)
G Alter et al, Nature, June 9, 2021

We report humoral and cellular immune responses from 20 Ad26.COV2.S vaccinated individuals from the COV1001 phase 1/2 clinical trial against the original SARS-CoV-2 strain WA1/2020 as well as against the B.1.1.7, CAL.20C, P.1., and B.1.351 variants of concern. We show that neutralizing antibody responses induced by Ad26.COV2.S were reduced against the B.1.351 and P.1 variants, but functional non-neutralizing antibody responses and T cell responses were largely preserved against SARS-CoV-2 variants.

- Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1310)
E Pritchard et al, Nature Medicine, June 9, 2021

Using 1,945,071 real-time PCR results from nose and throat swabs taken from 383,812 participants between 1 December 2020 and 8 May 2021, we found that vaccination with the ChAdOx1 or BNT162b2 vaccines already reduced SARS-CoV-2 infections =21?d after the first dose (61% (95% confidence interval (CI))=?54–68%) versus 66% (95% CI=?60–71%), respectively), with greater reductions observed after a second dose (79% (95% CI=?65–88%) versus 80% (95% CI=?73–85%), respectively). The largest reductions were observed for symptomatic infections and/or infections with a higher viral burden.

- Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February?March 2021 (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1311)
Tober-Lau P, et al. Emerg Infect Dis, Jun 8, 2021.

One week after second vaccinations were administered, an outbreak of B.1.1.7 lineage severe acute respiratory syndrome coronavirus 2 infections occurred in a long-term care facility in Berlin, Germany, affecting 16/20 vaccinated and 4/4 unvaccinated residents. Despite considerable viral loads, vaccinated residents experienced mild symptoms and faster time to negative test results.

- Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1312)
Schwarz T, et al. Emerg Infect Dis, Jun 8, 2021.

We detected delayed and reduced antibody and T-cell responses after BNT162b2 vaccination in 71 elderly persons (median age 81 years) compared with 123 healthcare workers (median age 34 years) in Germany. These data emphasize that nonpharmaceutical interventions for coronavirus disease remain crucial and that additional immunizations for the elderly might become necessary.

- Vaccine Breakthrough Infections with SARS-CoV-2 Variants. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1314)

Hacisuleyman Ezgi et al. The New England journal of medicine 2021 4 (23) 2212-2218

We describe two fully vaccinated persons in whom subsequent breakthrough infections with SARS-CoV-2 variants harboring a number of substitutions of interest developed. Our observations provide support for current strategies to monitor multiple variables proactively. These strategies include viral testing of symptomatic and asymptomatic persons, sequencing of viral RNA, and monitoring of neutralizing antibody titers, particularly in vaccinated persons who subsequently become infected.

News, Reviews and Commentaries

- Vitamin D and COVID-19 susceptibility and severity in the COVID-19 Host Genetics Initiative: A Mendelian randomization study. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1283)

Butler-Laporte Guillaume et al. PLoS medicine 2021 6 (6) e1003605

In this 2-sample MR study, we did not observe evidence to support an association between 25OHD levels and COVID-19 susceptibility, severity, or hospitalization. Hence, vitamin D supplementation as a means of protecting against worsened COVID-19 outcomes is not supported by genetic evidence. Other therapeutic or preventative avenues should be given higher priority for COVID-19 randomized controlled trials.

- Pan-ancestry exome-wide association analyses of COVID-19 outcomes in 586,157 individuals (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1285)

JA Kosmicki et al, AJHG, June 2, 2021

We used exome-sequence data to investigate associations between rare genetic variants and seven COVID-19 outcomes in 586,157 individuals, including 20,952 with COVID-19. We did not identify any clear associations with rare variants either exome-wide or when specifically focusing on (i) 13 interferon pathway genes in which rare deleterious variants have been reported in individuals with severe COVID-19; (ii) 281 genes located in susceptibility loci identified by the COVID-19 Host Genetics Initiative; or (iii) 32 additional genes of immunologic relevance and/or therapeutic potential.

- A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T-cell responses (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1288)

A Tauzin et al, Cell Host and Microbe, June 4, 2021

To assess the mechanisms contributing to protection, we analyzed humoral and T cell responses three weeks after a single BNT162b2 dose. We observed weak neutralizing activity elicited in

SARS-CoV-2 naïve individuals but strong anti-receptor binding domain and Spike antibodies with Fc-mediated effector functions and cellular CD4+ T cell responses. In previously-infected individuals, a single dose boosted all humoral and T-cell responses, with strong correlations between T helper and antibody immunity.

- Symptomatic Acute Myocarditis in Seven Adolescents Following Pfizer-BioNTech COVID-19 Vaccination (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1290)
M Marshall, Pediatrics, June 2021

- Spread of a SARS-CoV-2 variant through Europe in the summer of 2020 (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1296)
EB Hodcroft et al, Nature, June 7, 2021

We report on a novel SARS-CoV-2 variant, 20E (EU1), that emerged in Spain in early summer, and subsequently spread across Europe. We find no evidence of increased transmissibility, but instead demonstrate how rising incidence in Spain, resumption of travel, and lack of effective screening and containment may explain the variant's success. Despite travel restrictions, we estimate 20E (EU1) was introduced hundreds of times to European countries by summertime travelers, likely undermining local efforts to keep SARS-CoV-2 cases low.

- Would you have your DNA tested to predict how hard COVID-19 would strike? Should you? (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1297)
J Kaiser, Science, June 7, 2021

Several genetics experts tell Science that how a person's genes influence the course of COVID-19 remains too murky to deploy such risk assessments. "I think it's premature to use a genetic test to predict a person's likely COVID-19 severity. We don't understand exactly what these genetic variants mean or how they affect disease."

- SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1304)
S Gutmann et al, Nature Comms, June 7, 2021

We obtained blood samples (n=?2474) from hospitalized COVID-19 patients (n=?123), non-COVID-19 ICU sepsis patients (n=?25) and healthy controls (n=?30). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA was detected in plasma or serum (RNAemia) of COVID-19 ICU patients when neutralizing antibody response was low. RNAemia is associated with higher 28-day ICU mortality (hazard ratio [HR], 1.84 RNAemia is comparable in performance to the best protein predictors.

- Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1305)
O'Toole Áine et al. Wellcome open research 2021 6 121

Using a combination of data from routine surveillance, genomic sequencing and international travel we track the international dispersal of lineages B.1.1.7 and B.1.351 (variant 501Y-V2). We account for potential biases in genomic surveillance efforts by including passenger volumes from location of where the lineage was first reported, London and South Africa respectively. Using the

software tool grinch (global report investigating novel coronavirus haplotypes), we track the international spread of lineages of concern with automated daily reports.

- SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD and S2 (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1308)
F Amanat et al, Cell, June 7, 2021

We profiled vaccine-induced polyclonal antibodies as well as plasmablast derived mAbs from individuals who received SARS-CoV-2 spike mRNA vaccine. Polyclonal antibody responses in vaccinees were robust and comparable to or exceeded those seen after natural infection. However, the ratio of binding to neutralizing antibodies after vaccination was greater than that after natural infection and, at the monoclonal level, we found that the majority of vaccine-induced antibodies did not have neutralizing activity.

- Immunogenicity of Ad26.COVS vaccine against SARS-CoV-2 variants in humans (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1309)
G Alter et al, Nature, June 9, 2021

We report humoral and cellular immune responses from 20 Ad26.COVS vaccinated individuals from the COV1001 phase 1/2 clinical trial against the original SARS-CoV-2 strain WA1/2020 as well as against the B.1.1.7, CAL.20C, P.1., and B.1.351 variants of concern. We show that neutralizing antibody responses induced by Ad26.COVS were reduced against the B.1.351 and P.1 variants, but functional non-neutralizing antibody responses and T cell responses were largely preserved against SARS-CoV-2 variants.

- Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1310)
E Pritchard et al, Nature Medicine, June 9, 2021

Using 1,945,071 real-time PCR results from nose and throat swabs taken from 383,812 participants between 1 December 2020 and 8 May 2021, we found that vaccination with the ChAdOx1 or BNT162b2 vaccines already reduced SARS-CoV-2 infections =21?d after the first dose (61% (95% confidence interval (CI))=?54–68%) versus 66% (95% CI=?60–71%), respectively), with greater reductions observed after a second dose (79% (95% CI=?65–88%) versus 80% (95% CI=?73–85%), respectively). The largest reductions were observed for symptomatic infections and/or infections with a higher viral burden.

- Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February–March 2021 (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1311)
Tober-Lau P, et al. Emerg Infect Dis, Jun 8, 2021.

One week after second vaccinations were administered, an outbreak of B.1.1.7 lineage severe acute respiratory syndrome coronavirus 2 infections occurred in a long-term care facility in Berlin, Germany, affecting 16/20 vaccinated and 4/4 unvaccinated residents. Despite considerable viral loads, vaccinated residents experienced mild symptoms and faster time to negative test results.

- Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1312)
Schwarz T, et al. Emerg Infect Dis, Jun 8, 2021.

We detected delayed and reduced antibody and T-cell responses after BNT162b2 vaccination in 71 elderly persons (median age 81 years) compared with 123 healthcare workers (median age 34 years) in Germany. These data emphasize that nonpharmaceutical interventions for coronavirus disease remain crucial and that additional immunizations for the elderly might become necessary.

- Vaccine Breakthrough Infections with SARS-CoV-2 Variants. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1314)

Hacisuleyman Ezgi et al. The New England journal of medicine 2021 4 (23) 2212-2218

We describe two fully vaccinated persons in whom subsequent breakthrough infections with SARS-CoV-2 variants harboring a number of substitutions of interest developed. Our observations provide support for current strategies to monitor multiple variables proactively. These strategies include viral testing of symptomatic and asymptomatic persons, sequencing of viral RNA, and monitoring of neutralizing antibody titers, particularly in vaccinated persons who subsequently become infected.

Disclaimer: Articles listed in COVID-19 Genomics and Precision Public Health Weekly Update are selected by the CDC Office of Public Health Genomics to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

Page last reviewed: Oct 1, 2020

Page last updated: Jun 11, 2021

Content source: Office of Genomics and Precision Public Health (<http://www.cdc.gov/genomics/>), CDC Office of Science (<https://www.cdc.gov/od/science/index.htm>)